Tagged with Switzerland

Switzerland CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players also present in the biosimilars space.   We position ourselves as a pure play, differentiated, fully vertically integrated biosimilars development…

Switzerland In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical breakthroughs, and why scientific innovation continues to motivate him.   When you have started two companies, people think that you…

Switzerland AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a single year. Helsdingen also touches on talent acquisition challenges, the competitive Swiss market, and AbbVie’s digitalisation journey.   We have…

Europe While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as well as develop diagnostics, treatments, and vaccines for COVID-19. Recruitment also continued apace; here four recent country manager appointees share…

Switzerland Mera Pharma’s Khalid Saleh introduces the Swiss-headquartered but MENA-focused company, how it plans to expand via CMOs, and its evolution from food supplements, cosmetics and medical devices into the more strictly regulated world of pharmaceuticals.   Middle Eastern customers hold Switzerland and its pharmaceutical industry in high esteem. Manufacturing products…

Switzerland Chief Financial Officer Marina Lugova introduces pharmaceutical company Synbias Pharma’s evolving European footprint, how the company has been able to withstand the COVID-19 pandemic and continue providing its essential products to customers, and its plans for the future, including further investments in the firm’s German production facility and new strategic…

Switzerland As part of the Federal Department of Home Affairs, the Federal Office of Public Health (FOPH) is responsible for public health in Switzerland; developing the country’s health policy and working to create an efficient and affordable healthcare system in the long term. PharmaBoardroom recently sat down with the FOPH’s newly…

Switzerland Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the strain on resources that genomic medicine can contribute to. Professor Szucs also evaluates the sustainability of personalized medicine and China’s rapid progress in the field.  …

Switzerland Prof Dr Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) outlines the organisation’s important role within the global health landscape, how Switzerland collaborates with low- and middle-income countries, the growing significance of data, and what lessons can be taken from the COVID-19 crisis.   In a…

Switzerland Innosuisse CEO Annalise Eggimann presents the organisation’s renewed mandate as the main Swiss innovation promotion agency, how Innosuisse serves Switzerland’s vast array of SMEs, and why the country needs to guard against complacency to stay ahead of the competition on innovation.   A successful culture needs to guard against complacency.…

Switzerland PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their strategies for success in one of the world’s most innovative nations.   Henrik Asmussen, General Manager, Amgen Switzerland   Danish national Henrik Asmussen, head of Amgen Switzerland since 2017, outlined the…

UK When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left behind in terms of alignment with the world’s top regulatory bodies. Perhaps cognizant of this, the UK regulatory agency for…